CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale · Stock Option (Right to Buy) 10b5-1 | −17,566 | 0 | ||
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,812 | $25.69 | $72K | 108,024 |
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −2,356 | $72.08 | $170K | 105,668 |
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −456 | $72.67 | $33K | 105,212 |
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,812 | 19,689 | ||
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −679 | $73.06 | $50K | 405,891 |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −7,221 | $73.08 | $528K | 398,670 |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −2,100 | $73.08 | $153K | 396,570 |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −2,572 | $72.46 | $186K | 393,998 |
| 2026-05-13 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Grant or award 10b5-1 | +12,500 | 406,570 | ||
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,740 | $46.54 | $128K | 107,952 |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −840 | $78.23 | $66K | 107,112 |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,900 | $79.31 | $151K | 105,212 |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +800 | $46.54 | $37K | 106,012 |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −200 | $78.00 | $16K | 105,812 |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −600 | $79.28 | $48K | 105,212 |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,740 | 42,260 | ||
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −800 | 41,460 | ||
| 2026-04-21 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −2,850 | $70.91 | $202K | 394,070 |
| 2026-04-06 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,265 | $39.42 | $89K | 107,477 |
Page 7 of 25 · 493 trades